Susvimo Patient Assistance Program
Don’t let the high cost of brand ranibizumab port delivery system disrupt your neovascular AMD treatment. We help eligible patients access Susvimo (ranibizumab port delivery system) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Susvimo (ranibizumab injection for intravitreal use via ocular implant) is FDA-approved for treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy. First refillable ocular implant delivering continuous ranibizumab — implanted surgically, refilled every 6 months, replacing monthly intravitreal injections.
- Without assistance, Susvimo initial implant and refills commonly run approximately $12,000+ per implant plus refills.
- Through AffordMyPrescriptions, qualifying patients can access Susvimo for a flat $69.95 per month.
- Standard anti-VEGF therapy for retinal disease: bevacizumab (Avastin — off-label intravitreal, very cheap generic biosimilars), ranibizumab (Lucentis — brand and Byooviz, Cimerli biosimilars), aflibercept (Eylea — brand, plus Eylea HD 8mg, plus biosimilars Yesafili, Opuviz), faricimab (Vabysmo — bispecific anti-VEGF/anti-Ang2), brolucizumab (Beovu — brand). Standard intravitreal injections monthly to every 3–4 months. Susvimo eliminates monthly injections — 6-month refills after surgical implant. Retinal specialist surgery required. Compounded bevacizumab widely used off-label given cost.
What is Susvimo Prescription Assistance Program?
The Susvimo Patient Assistance Program helps eligible patients access this port delivery system at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but requires detailed applications, retinal specialist surgical coordination, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Susvimo PAP enrollment for a flat $69.95 per month — so you never face a gap in Susvimo therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Susvimo enrollment — so you never face a gap in your retinal disease treatment.
Pharmacy Price Comparison
- Without assistance, Susvimo implant and refills cost thousands. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Vabysmo (alt anti-VEGF) | ~$2,200/injection | Alt anti-VEGF q3-4 mo |
| Retinal specialist center | ~$12,000/implant | Save substantially |
| Ophthalmology infusion center | ~$11,000/implant | Save substantially |
| Hospital outpatient | ~$13,000/implant | Save substantially |
| Susvimo refills | ~$2,000/refill | Every 6 months refill |
| Bevacizumab compounded (alt) | ~$50/injection | Very cheap off-label alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Susvimo — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Susvimo Prescription Program?
The Susvimo Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Compounded bevacizumab is very cheap for standard anti-VEGF therapy. Susvimo dramatically reduces treatment frequency (twice yearly refills vs monthly injections) — major patient benefit. Retinal specialist surgical expertise required.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Susvimo assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Susvimo is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Susvimo:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $12,000/implant + refills per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Susvimo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Susvimo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Susvimo:
Susvimo is the first refillable ocular implant for retinal disease — surgically implanted device continuously delivers ranibizumab, refilled every 6 months, replacing monthly intravitreal injections. Novel drug delivery paradigm for chronic retinal disease.
How It Works:
Neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy are leading causes of vision loss driven by vascular endothelial growth factor (VEGF)-mediated pathological neovascularization and vascular leakage. Anti-VEGF therapy revolutionized outcomes — but requires frequent intravitreal injections (monthly to every 3–4 months) — burden for patients and clinical systems. Susvimo is a refillable ocular implant surgically placed in the vitreous cavity through the pars plana — contains ranibizumab reservoir that continuously releases medication into the vitreous. Refilled every 6 months by needle injection through the eye. Provides continuous anti-VEGF exposure without monthly intravitreal injections. Vabysmo (faricimab bispecific) and Eylea HD (high-dose aflibercept) also aim to reduce injection frequency but via longer-interval standard injections.
Form and Use:
Susvimo implant surgically placed by retinal specialist. Refills every 6 months. Ophthalmology follow-up. Consider baseline standard anti-VEGF injections before Susvimo implant.
Generic Availability:
No generic Susvimo. Standard anti-VEGF options: bevacizumab (Avastin — off-label intravitreal, compounded, very cheap; brand IV Avastin much more expensive), ranibizumab (Lucentis brand; and Byooviz, Cimerli biosimilars), aflibercept (Eylea — brand and Eylea HD 8mg — brand; and Yesafili, Opuviz biosimilars), faricimab (Vabysmo — anti-VEGF/anti-Ang2 bispecific; every 3–4 months many patients), brolucizumab (Beovu — brand). Susvimo offers 6-month refills via implant — differentiator. American Academy of Ophthalmology guidance. AMD alliance and other patient resources.
Warnings:
Endophthalmitis (serious eye infection — risk with any intravitreal procedure including implant surgery and refills), rhegmatogenous retinal detachment, vitreous hemorrhage, conjunctival wound issues (dehiscence, retraction — implant complications), traumatic cataract, intraocular pressure changes, embryo-fetal considerations, cardiovascular risk (theoretical with systemic VEGF blockade — likely minimal given local delivery), septum dislodgement (implant complication). Other: conjunctival hemorrhage/injection, eye pain, IOP changes. Retinal specialist expertise and comprehensive ophthalmology follow-up essential.
FAQ (Frequently Asked Questions)
How much does Susvimo cost without insurance?
Initial implant $10,000–$13,000 (surgical procedure + implant) + refills ~$2,000 every 6 months. Compare to standard anti-VEGF injections (monthly Vabysmo ~$2,200/dose, Eylea ~$1,900/dose, compounded bevacizumab ~$50/dose off-label). Susvimo eliminates monthly injection burden.
How is Susvimo different from standard anti-VEGF injections?
Standard anti-VEGF (Lucentis, Eylea, Vabysmo, Avastin off-label) requires intravitreal injections monthly to every 3–4 months. Susvimo is a surgical implant that continuously releases ranibizumab — refilled every 6 months. Dramatically reduces treatment burden for chronic retinal disease. First refillable ocular implant paradigm.
How does Susvimo compare to Vabysmo (faricimab)?
Both aim to reduce injection burden vs monthly. Vabysmo is a bispecific anti-VEGF/anti-Ang2 antibody — standard intravitreal injections every 3–4 months in many patients. Susvimo delivers continuous ranibizumab via 6-monthly refilled implant. Susvimo requires surgical implant procedure; Vabysmo is standard intravitreal injection. Choice by patient preference, disease response, and shared decision-making.
Why do people still use compounded bevacizumab (Avastin)?
Bevacizumab (Avastin) is used off-label intravitreally for retinal disease at dramatically lower cost than approved products — commonly ~$50 per dose compounded. Similar efficacy to ranibizumab in some head-to-head trials. However off-label with theoretical concerns about compounding contamination. Widely used given cost differential.
What are Susvimo risks?
Endophthalmitis risk with implant surgery and refills, retinal detachment, vitreous hemorrhage, conjunctival wound complications, IOP changes, septum dislodgement, cataract. Serious eye complications possible — retinal specialist expertise essential.
Take Control of Your Medication Costs
Refillable ocular implant transforms treatment burden for chronic retinal disease. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.